Godavari Biorefineries Limited has informed the Exchange regarding a revised press release dated May 26, 2025, titled "Revseid Press Release for the Q4 and FY25".
GODAVARIB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Biorefineries filed a revised press release for Q4 and FY25, correcting a misclassification of tax expense. The earlier version had wrongly shown Q4 FY25 tax expense as Rs. (0.7) Cr with Rs. 24.5 Cr booked as a one-time deferred tax item; the correct tax expense is Rs. 23.8 Cr with no one-time deferred tax impact. The company clarified this is a presentation change only and does not affect profitability figures. On the numbers, Q4 FY25 revenue came in at Rs. 579.5 Cr (down ~5.8% YoY) with EBITDA of Rs. 121.7 Cr at a 21% margin (up from 20.2%) and PAT of Rs. 71.9 Cr. For the full year FY25, revenue grew ~10.9% to Rs. 1,870.3 Cr, but full-year EBITDA margin compressed sharply to 6.4% from 8.8%, and reported PAT turned negative at Rs. (23.4) Cr. The Bio-based Specialty Chemicals segment was a clear bright spot, with segment EBITDA more than doubling YoY in FY25.
The errata is largely cosmetic and should not change investor views on the underlying business. However, the full-year picture is weak – flat-to-negative PAT and significant margin compression despite revenue growth – which may weigh on the stock. The strong Q4 margins and doubling of Bio-based Chemicals EBITDA provide a positive counter-narrative, and the upcoming 200 KLPD grain distillery (Q4 FY26 commissioning) offers a future growth lever.